Aquestive Therapeutics to Report Fourth Quarter 2025 Financial Results and Recent Business Highlights on March 4 and Host Conference Call on March 5 at 8:00 a.m. ET

Core Viewpoint - Aquestive Therapeutics, Inc. is set to report its fourth quarter results for the year ended December 31, 2025, and provide business updates on March 4, 2026, after market close [1] Company Overview - Aquestive Therapeutics is a pharmaceutical company focused on improving patients' lives through innovative science and delivery technologies [3] - The company is a leader in delivering medications via oral film and operates as both a developer of proprietary products and a Contract Development and Manufacturing Organization (CDMO) [3] - It is headquartered in New Jersey with manufacturing facilities in Indiana and is the exclusive manufacturer of four commercialized products marketed by its licensees across six continents [3] - The company utilizes proprietary technologies like PharmFilm and has developed the AdrenaVerse™ platform, which includes over 20 epinephrine prodrugs for various allergy and dermatological indications [3] Product Development - Aquestive is advancing Anaphylm™ (dibutepinephrine) sublingual film for treating severe allergic reactions, including anaphylaxis [3] - The company is also developing AQST-108 (epinephrine prodrug) topical gel for potential dermatological conditions, including alopecia areata [3]